Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Primary Sclerosing Cholangitis-Associated Inflammatory Bowel Disease in Children: Characterizing the Clinical Phenotype and Inflammatory State
FY 2015-16
Summary
Most individuals with primary sclerosing cholangitis (PSC), an incurable liver disease, also have inflammatory bowel disease (IBD). In adults, IBD occurring in association with PSC (PSC-IBD) appears to be a distinct type of IBD, with extensive colitis and an increased risk of colon cancer, but relatively mild clinical symptoms. Given the possible link between colonic inflammation and PSC, greater attention is being paid to healing the colon in adults with PSC-IBD in the hopes of lessening the progression of liver disease. PSC-IBD has never been carefully studied in children. Given the typically silent nature of PSC-IBD in adults, symptoms may underestimate colitis activity in children with PSC-IBD.The goal of the proposed project is to test the hypothesis that symptoms are a poor marker of colon inflammation in paediatric PSC-IBD and that fecal calprotectin (FC), a stool biomarker, is more accurate in this population, whencompared to colonoscopy.Roughly 30 children with PSC and IBD (cases) and 60 children with colitis without PSC (controls) will be followed for 12 months. Every 6 to 12 months, colitis activity will be clinically assessed using a symptoms-based scoring tool called the Paediatric Ulcerative Colitis Activity Index (PUCAI) and FC will be measured at the same time. Colonoscopies will be performed as clinically indicated and scored using the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). A PUCAI score and FC will be obtained at the time of colonoscopy as well. The correlation between all these markers of disease activity (PUCAI, FC and UCEIS) will be determined in both groups, and compared between groups to establish the optimal strategy for monitoring colitis activity in children with PSC-IBD.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
349978
Name
Ricciuto Amanda
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Primary Sclerosing Cholangitis-Associated Inflammatory Bowel Disease in Children: Characterizing the Clinical Phenotype and Inflammatory State
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Colitis; Fecal Calprotectin; Inflammatory Bowel Disease; Paediatrics; Primary Sclerosing Cholangitis
Abstract
Most individuals with primary sclerosing cholangitis (PSC), an incurable liver disease, also have inflammatory bowel disease (IBD). In adults, IBD occurring in association with PSC (PSC-IBD) appears to be a distinct type of IBD, with extensive colitis and an increased risk of colon cancer, but relatively mild clinical symptoms. Given the possible link between colonic inflammation and PSC, greater attention is being paid to healing the colon in adults with PSC-IBD in the hopes of lessening the progression of liver disease. PSC-IBD has never been carefully studied in children. Given the typically silent nature of PSC-IBD in adults, symptoms may underestimate colitis activity in children with PSC-IBD.The goal of the proposed project is to test the hypothesis that symptoms are a poor marker of colon inflammation in paediatric PSC-IBD and that fecal calprotectin (FC), a stool biomarker, is more accurate in this population</strong>, whencompared to colonoscopy.Roughly 30 children with PSC and IBD (cases) and 60 children with colitis without PSC (controls) will be followed for 12 months. Every 6 to 12 months, colitis activity will be clinically assessed using a symptoms-based scoring tool called the Paediatric Ulcerative Colitis Activity Index (PUCAI) and FC will be measured at the same time. Colonoscopies will be performed as clinically indicated and scored using the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). A PUCAI score and FC will be obtained at the time of colonoscopy as well. The correlation between all these markers of disease activity (PUCAI, FC and UCEIS) will be determined in both groups, and compared between groups to establish the optimal strategy for monitoring colitis activity in children with PSC-IBD.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ricciuto, Amanda
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~